Prolific medical device inventor to drive innovation and product
development for NewCardio
SANTA CLARA, Calif., Oct. 21 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced Dorin Panescu, PhD, has agreed to join NewCardio as its Chief Technical Officer and Vice-President of Research and Development, effective October 20. Dr. Panescu joins NewCardio from St. Jude Medical, Inc., (NYSE: STJ) a $4.1 billion medical technology and services company, where he most recently served as Director, Technology Development, for the Company's Cardiac Rhythm Management Division. In this role, he managed broad functional teams tasked with the development of heart failure trending and wireless remote monitoring features for implantable cardiac defibrillators and pacemakers. Dr. Panescu is credited with 130 issued U.S. patents and 70 published or pending U.S. patent applications covering a wide spectrum of technologies for medical devices, specifically related to devices and methods for medical imaging, diagnosis and therapies, as well as cardiac mapping and ablation.
Before joining St. Jude Medical, Inc. Dr. Panescu served as Vice President of Research and Development, Operations and Intellectual Property for Refractec, Inc., where he directed R&D and Operations for the development of keratoplasty radiofrequency ablation equipment and set the company's IP strategy. Refractec, Inc. was the first company to get PMA approval from the US Food and Drug Administration for the surgical treatment of presbyopia. Previously, he served as Senior Director of Systems Development for Boston Scientific Corporation, directing new product development for the Electrophysiology Division. Boston Scientific, Electrophysiology, is the world market leader in radiofrequency cardiac ablation systems.
Mark W. Kroll, PhD, FACC, FHRS and Chairman of NewCardio's Board of
|SOURCE NewCardio, Inc.|
Copyright©2008 PR Newswire.
All rights reserved